Anti-SVEP1/ C9orf13/ CCP22 functional antibody

Anti-SVEP1/ C9orf13/ CCP22 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to SVEP1/SVEP1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1568-Ab-1/ GM-Tg-hg-SE1568-Ab-2Anti-Human SVEP1 monoclonal antibodyHuman
GM-Tg-rg-SE1568-Ab-1/ GM-Tg-rg-SE1568-Ab-2Anti-Rat SVEP1 monoclonal antibodyRat
GM-Tg-mg-SE1568-Ab-1/ GM-Tg-mg-SE1568-Ab-2Anti-Mouse SVEP1 monoclonal antibodyMouse
GM-Tg-cynog-SE1568-Ab-1/ GM-Tg-cynog-SE1568-Ab-2Anti-Cynomolgus/ Rhesus macaque SVEP1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1568-Ab-1/ GM-Tg-felg-SE1568-Ab-2Anti-Feline SVEP1 monoclonal antibodyFeline
GM-Tg-cang-SE1568-Ab-1/ GM-Tg-cang-SE1568-Ab-2Anti-Canine SVEP1 monoclonal antibodyCanine
GM-Tg-bovg-SE1568-Ab-1/ GM-Tg-bovg-SE1568-Ab-2Anti-Bovine SVEP1 monoclonal antibodyBovine
GM-Tg-equg-SE1568-Ab-1/ GM-Tg-equg-SE1568-Ab-2Anti-Equine SVEP1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1568-Ab-1/ GM-Tg-hg-SE1568-Ab-2; GM-Tg-rg-SE1568-Ab-1/ GM-Tg-rg-SE1568-Ab-2;
GM-Tg-mg-SE1568-Ab-1/ GM-Tg-mg-SE1568-Ab-2; GM-Tg-cynog-SE1568-Ab-1/ GM-Tg-cynog-SE1568-Ab-2;
GM-Tg-felg-SE1568-Ab-1/ GM-Tg-felg-SE1568-Ab-2; GM-Tg-cang-SE1568-Ab-1/ GM-Tg-cang-SE1568-Ab-2;
GM-Tg-bovg-SE1568-Ab-1/ GM-Tg-bovg-SE1568-Ab-2; GM-Tg-equg-SE1568-Ab-1/ GM-Tg-equg-SE1568-Ab-2
Products NameAnti-SVEP1 monoclonal antibody
Formatmab
Target NameSVEP1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SVEP1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1568-Ag-1Recombinant multi-species SVEP1/ C9orf13/ CCP22 protein


    Target information

    Target IDGM-SE1568
    Target NameSVEP1
    Gene ID79987,64817,685899,709478,474799,101100007,781282,100053852
    Gene Symbol and Synonyms1110021D17Rik,4833413O10Rik,C9orf13,CCP22,D430029O09Rik,POLYDOM,SEL-OB,SELOB,SVEP1
    Uniprot AccessionQ4LDE5,P0C6B8
    Uniprot Entry NameSVEP1_HUMAN,SVEP1_RAT
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000165124
    Target ClassificationN/A

    The target: SVEP1, gene name: SVEP1, also named as C9orf13, CCP22, POLYDOM, SEL-OB, SELOB. Predicted to enable calcium ion binding activity and chromatin binding activity. Predicted to be involved in epidermis development and lymph vessel morphogenesis. Predicted to act upstream of or within several processes, including Tie signaling pathway; lymph circulation; and lymph vessel development. Located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.